Entrectinib

Drug Profile

Entrectinib

Alternative Names: NMS-E628; RXDX-101; TrkA/TrkB/TrkC/ROS1/ALK inhibitor

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Nerviano Medical Sciences
  • Developer Ignyta; Nerviano Medical Sciences
  • Class Antineoplastics; Benzamides; Indazoles; Piperazines; Pyrans; Small molecules
  • Mechanism of Action Anaplastic lymphoma kinase inhibitors; ROS1-protein-inhibitors; TrkA receptor antagonists; TrkB receptor antagonists; TrkC receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroblastoma; Non-small cell lung cancer; Colorectal cancer
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Colorectal cancer; Non-small cell lung cancer; Solid tumours
  • Phase I Neuroblastoma

Most Recent Events

  • 03 Mar 2017 Angsana Molecular & Diagnostics will enter into a partnership with Ignyta for STARTRK 2 trial sites in Asia
  • 23 Feb 2017 Ignyta initiates an expanded access of entrectinib for Solid tumours in USA (NCT03066661)
  • 10 Feb 2017 Updated safety and efficacy data from two phase I trials in Solid tumours released by Ignyta
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top